Standard BioTools Inc. (LAB) News
Filter LAB News Items
LAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LAB News Highlights
- For LAB, its 30 day story count is now at 4.
- Over the past 21 days, the trend for LAB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about LAB are CELL.
Latest LAB News From Around the Web
Below are the latest news stories about STANDARD BIOTOOLS INC that investors may wish to consider to help them evaluate LAB as an investment opportunity.
Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of March 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Plan). The equity award consisted of an award of nonstatutory stock options to purchase 647,112 shares of common stock and an award of 112,293 r |
Standard BioTools Announces Appointment of Fenel Eloi to Board of DirectorsExperienced Life Science Operating Leader Joins Board as Company Enters New PhaseSOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of Fenel Eloi to its Board of Directors (“Board”). Eloi will also serve on the Board’s Audit Committee. Eloi was most recently the Chief Financial Officer and then Chief Operating Officer of Cell |
Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor ForumSOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 3:00 p.m. ET. The presentation will be webcast live and available on the Investor Relations |
Standard BioTools to Present at 43rd Annual Cowen Health Care ConferenceSOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will present at the Cowen Health Care Conference on Wednesday, March 8, 2023, at 12:50 p.m. ET. The presentation will be webcast live and available on the Investor Relations page of the company’s website at Events & Presentations |
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan (Plan), as a material inducement to four individuals entering into employment with Standard BioTools™. The equity awards were approved in accorda |
Standard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call TranscriptStandard BioTools Inc. (NASDAQ:LAB) Q4 2022 Earnings Call Transcript February 14, 2023 Operator: Hello, and welcome to the Standard BioTools Inc. Fourth Quarter and Full Year 2022 Financial Results Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeNardo, Investor Relations. Thank you. Mr. […] |
How a Peninsula biotech tools company looks to corral 'one-trick ponies'The 24-year-old company, founded as Fluidigm, got a $250 million influx from two hedge funds and brought in new management. |
Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business OutlookFourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product and service revenues of $94.5 million Improved operating discipline and restructuring initiatives contributed to a 16% sequential decrease in operating expenses in the fourth quarter; Product and services margin improved sequentially by 620 basis points on a GAAP basis, 520 basis points on a non-GAAP |
The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitableStandard BioTools Inc. ( NASDAQ:LAB ) shareholders will doubtless be very grateful to see the share price up 82% in the... |
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial ResultsSOUTH SAN FRANCISCO, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 14, 2023, after the close of the market. The Company’s management will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on February 14, 2023, to discuss fourth quarter and full year 20 |